Zandelisib
Zandelisib (ME-401) is a selective, orally active, non-covalent inhibitor of PI3Kδ. Zandelisib can sustainably inhibit AKT phosphorylation and downstream signaling pathways. Zandelisib can be used in the study of malignancies such as relapsed/refractory B-cell lymphoma[1].
Product Specifications
CAS Number
1401436-95-0
Product Name Alternative
ME-401; PWT-143
UNSPSC
12352005
Target
Akt; PI3K
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zandelisib.html
Purity
99.72
Solubility
DMSO : 9.09 mg/mL (ultrasonic)
Smiles
CN1CCC(C2=CC=CC=C2CC(NC3=NC(N4C5=CC=CC=C5N=C4C(F)F)=NC(N6CCOCC6)=N3)(C)C)CC1
Molecular Formula
C31H38F2N8O
Molecular Weight
576.68
References & Citations
[1]Kunieda K, et al. A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects. Am J Cancer Res. 2025 May 15;15 (5) :2097-2110.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
